IL-22 Defect During *Streptococcus pneumoniae* Infection Triggers Exacerbation of Chronic Obstructive Pulmonary Disease

Muriel Pichavant, Riti Sharan, Olivier Le Rouziac, Cécile Olivier, Florence Hennegrave, Gaëlle Rémy, Magdiel Pérez-Cruz, Bachirou Koné, Pierre Gosset, Nicolas Just, Philippe Gosset

*Institut Pasteur de Lille, Centre d’Infection et d’Immunité de Lille, F-59019 Lille, France*
*A Université Lille Nord de France, F-59000 Lille, France*
*B Centre National de la Recherche Scientifique, UMR 8204, F-59021 Lille, France*
*C Institut National de la Santé et de la Recherche Médicale, U1019, F-59019 Lille, France*
*D Institut Fédératif de Recherche 142, F-59019 Lille, France*
*E Service de Pneumologie, Hôpital Calmette, CHRU, Lille, France*
*f Service d’Anatomo-Pathologie, Hôpital Saint Vincent de Paul, Lille, France*
*g Service de Pneumologie, Hôpital Victor Provo, Roubaix, France*

**ABSTRACT**

Progression of chronic obstructive pulmonary disease (COPD) is linked to episodes of exacerbations caused by bacterial infections due to *Streptococcus pneumoniae*. Our objective was to identify during COPD, factors of susceptibility to bacterial infections among cytokine network and their role in COPD exacerbations. *S. pneumoniae* was used to sub-lethally challenge mice chronically exposed to air or cigarette smoke (CS) and to stimulate peripheral blood mononuclear cells (PBMC) from non-smokers, smokers and COPD patients. The immune response and the cytokine production were evaluated. Delayed clearance of the bacteria and stronger lung inflammation observed in infected CS-exposed mice were associated with an altered production of IL-17 and IL-22 as susceptibility factors in COPD exacerbation. Therefore targeting such cytokines could represent a potent strategy to control COPD exacerbation.

© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
understand mechanisms leading to exacerbation in COPD patients in order to propose novel therapeutics (Barnes and Stockley, 2005).

Among the factors orchestrating the anti-bacterial response, Th17 cytokines, including interleukin (IL)-17 and IL-22, play a major role (Eidenschenk et al., 2014; Ivanov et al., 2013). These cytokines are produced by various cells of the adaptive and innate immune system. These include conventional T lymphocytes, natural killer (NK) cells, non-conventional T cells (such as γδ T cells, NK T cells and invariant mucosal-associated T (MAIT) cells) and type 3 innate lymphoid cells (ILC3). Production of Th17 cytokines is strongly dependent on IL-1β, IL-23 and IL-6 secretion by antigen presenting cells (APC) (Doisne et al., 2011; Ivanov et al., 2014). Anti-bacterial effects of Th17 cytokines comprise the induction of antimicrobial peptides and neutrophil chemoattractants by airway epithelial cells (Ajula et al., 2008; Wolk et al., 2004). Both IL-17 and IL-22 amplify the granulopoiesis by increasing the expression of G-CSF. In addition, IL-22 plays a central role in the maintenance of the epithelium integrity by limiting cellular apoptosis and by favoring repair/regeneration processes (Sonnenberg et al., 2011).

Since Th17 cytokines play major functions in the control of bacterial, including pneumococcal, outgrowth, we hypothesized that their production upon respiratory bacterial challenge could be altered in the context of COPD. Indeed, our data indicate a default in Th17 cytokine production, especially IL-22, in response to S. pneumoniae in a mouse model of COPD induced by chronic CS exposure (Pichavant et al., 2014) and ex vivo in COPD patients. This reduced response was associated with diminished production of Th17 cytokine inducing factors by pulmonary APC. Remarkably, administration of recombinant IL-22 in CS-exposed mice just before the bacterial challenge resulted in accelerated pneumococcal clearance and lowered pulmonary inflammation. Thus, targeting Th17 cytokines might be valuable to limit COPD exacerbation due to bacterial infections.

2. Material and Methods

2.1. Mice

Six- to eight-week-old male wild-type (WT) C57BL/6 (H-2Db) mice were purchased from Janvier (Le Genest-St.-Isle, France). All animal work conformed to the guidelines of Animal Care and Use Committee from Nord Pas-de-Calais (agreement no. AF 16/20,090). Mice were exposed to CS (5 cig/day, 5 days/week) during 12 weeks as previously described in order to generate a COPD-like disease (Wolk et al., 2004), or ambient air as control. Six to ten mice were used per group and per experiment. Experiments were repeated at least 3 times.

2.2. Patients with COPD

Peripheral blood was collected in stable COPD patients (n = 12), in smokers (without COPD, n = 13) and in non-smoker healthy controls (n = 14) (CPP 2008-A0690-55) (see Table 1). Written informed consent was received from participants prior to inclusion in the study, according ethics committee on human experimentations. COPD patients at steady state included subjects with a GOLD score between 2 and 4 and did not received oral corticosteroids.

| Group | COPD | Smokers | Non smokers |
|-------|------|---------|-------------|
| Nb    | 12   | 14      | 14          |
| Sexes (M/F) | 11/1 | 11/3 | 10/4 |
| Age | 59.2 ± 17.1 | 43.9 ± 4.7 | 45.5 ± 5.7 |
| Smoking (pack/year) | 57 ± 5.9 | 37.6 ± 5.2 | 0 |
| FEV1% | 51.3 ± 4.1 | 94.7 ± 1.3 | 93.5 ± 3.5 |
| PO2 | 77.1 ± 6.6 | ND | ND |
| BODE | 3.1 ± 0.5 | ND | ND |
| Body mass index | 25.6 ± 1.2 | ND | ND |
| VEMS% | 56.9 ± 4.6 | ND | ND |
| MRC score | 1.5 ± 0.31 | ND | ND |
| 6 MWT | 410 ± 34.8 | ND | ND |
| Inhaled corticosteroid | 4 | D | 0 |

Peripheral blood mononuclear cells (PBMC) were purified on Ficoll Paque gradient (GE healthcare). Cells (3 × 10⁶ in 1 ml) were cultured in RPMI1640 (GIBCO, Invitrogen Corporation) supplemented with 10% FCS, 200 U/ml penicillin/streptomycin (PS) and then exposed to S. pneumoniae (Sp, MOI = 2) or to phytohemagglutinin (1 μg/ml) (PHA, Difco) as a positive control. After 90 min, antibiotics were added to stop bacteria growth and supernatants were collected 24 h later. Cell viability was not affected. Some cells were incubated with brefeldin A (10 μg/ml, Sigma) for 4 h and used for intracellular staining of cytokines.

2.3. Reagents and Antibodies

Monoclonal antibodies (mAbs) against mouse CD3 (APC-conjugated), CD5 (FITC-conjugated), NK1.1 (PerCP-Cy5.5-conjugated), TCR-β (V450-conjugated), CD25 (APC-conjugated), CD69 (Alexa700-conjugated), CD11b (V450-conjugated), Ly-6G (APC-Cy7-conjugated), CD8 (V500-conjugated), CD4 (APC-conjugated), CD103 (PE-conjugated), CD11c (APC-conjugated), CD45 (Q-dot605-conjugated), F4/80 (PerCP-Cy5.5-conjugated), Siglec F (PE-conjugated), CD64 (APC-conjugated), CD86 (PE-conjugated), CD40 (PE-conjugated), I-Ab (FITC-conjugated), IFN-γ (PE-conjugated), IL-17 (APC-conjugated), CD11c (PC-Cy7-conjugated), F4/80 (PerCP-Cy5.5-conjugated), CD11b (V450-conjugated) and CD103 (PE-conjugated) and isotype controls were purchased from Biolegend (Le Pont de Claix, France). mAbs against human CD were also used including anti-CD11c, CD14, CD20 (PE-CF594-conjugated), CD117, TCR-γδ (V450-conjugated), CD4, CD3 (Alexa-700 conjugated), CD8, CD127 (V500 conjugated), CD196, CD3 (BV605 conjugated), CD25, CD86 (APC-conjugated), CD56, Vε7.2 (PerCP-Cy5.5 conjugated), TCR Vα24ζα18, CD161 (PE-Cy7-conjugated) and CD45 (APC-H7 conjugated) (BD Biosciences, Biolegend and Myltenyi Biotech) as well as the Alexa488 anti-IFN-γ, Alexa647 anti-IL-17 (BD Biosciences) and PE anti-IL-22 antibodies (e-Biosciences) and the isotype controls. 3R4F research cigarettes were purchased from University of Kentucky (USA) and used to induce COPD like symptoms (Pichavant et al., 2014). Gating strategy for flow cytometry analysis of Th17 producing cells is depicted in Supplemental Fig. 5.

2.4. Primers

Quantitative RT-PCR was performed to quantify mRNA of interest (Table 2). Results were expressed as mean ± SEM of the relative gene expression calculated for each experiment in folds (2−ΔΔCt) using GAPDH as a reference, and compared to controls.

2.5. Infection by S. pneumoniae and bacterial counts

Mice were inoculated by the intranasal route with a clinical isolate of Sp serotype 1 described elsewhere (Marques et al., 2012). Mice were anesthetized and administered intranasally with 5 × 10⁵ or 5 × 10⁶ in 1 ml were cultured
Table 2
Primer sequences for qRT-PCR in mice.

| Primer | F          | R          |
|--------|------------|------------|
| GAPDH  | F TCCCCAAGAATCATCCTTG | R TCAGATCCAGACGACACA |
| DefB2  | F AAAGTTTCTGATCAAAGGAACAT | R GGAGACAAATGTCGTCACA |
| DefB3  | F TCAGAAGGGGAGGCAATGCT | R GGAACTCCACAACTGCCAATC |
| Cathelicidin | F CAGACCGGGGACTTACAG | R TCACACACCTGTTCTT |
| s100a9 | F CACCCTGACGAAGAAGAAT | R TTCTCCATTGAGGCCTCATTT |
| II-1b  | F TCCCTCGATCGATCAGACA | R AACGATTATTCACTTGAATGCT |
| II-6   | F AGGCTCCGTTGAGTGAAGTG | R CTAGTCGGTGTAACACAC |
| II-12p40 | F GACCTTGCGATATGAAGGCG | R CAACTGTTGACCTTGAATGCT |
| II-23p19 | F CACCCGCGGACATACATAA | R CCTTGGGGTGCACACAT |

colonies were analyzed in lung tissues 24 h after infection (d). Histological changes were evaluated on lung sections stained for IFN-γ, IL-17, and IL-22 concentration by ELISA (R&D Systems).

2.6. Assessment of airway inflammation

Mice were sacrificed for sampling BAL, lungs, spleen and blood. Total cell numbers per BAL was determined. For histopathology, lungs were fixed by inflation and immersion in paraformaldehyde (PFA; 4%) and embedded in paraffin. To evaluate airway inflammation, lung sections (4-μm thick) were stained with hematoxylin & eosin.

Pulmonary cells from air or CS-exposed mice were prepared as previously described (vander Pol and Opal, 2009) and were analyzed by flow cytometry. To analyze cytokine profiles, pulmonary cell suspensions were incubated with phorbol 12-myristate 13-acetate (PMA; 20 ng/ml) and ionomycin (500 ng/ml) for 3 h. Cells were then stained with appropriate extracellular markers, fixed, permeabilized (BD Cytofix/cytoperm, BD Bioscience), and incubated with PE-conjugated CD45+ Siglec F+ (Becton Dickinson), and analyzed using the FlowJo software.

Cytokine production was analyzed in total lung cells. For this, 5 × 10^5 lung cells were seeded on 96-well plates coated or not with anti-CD3 Ab (eBiosciences). Forty-eight hours later, supernatants were collected and analyzed for IFN-γ (eBiosciences). Relative to air mice, infection was associated with enhanced cellular recruitment (particularly neutrophils) in the BAL and the lungs of CS-exposed mice (Fig. 1c–d). Histological examination of lung tissues showed that inflammatory infiltrates mainly located in peribronchial areas and alveolar spaces (Fig. 1e). Moreover, a large thickening of the alveolar walls was observed in CS-exposed animal mice. In air mice challenged with bacteria, lung inflammation was nearly resolved 3 days post-infection (dpi). Enhanced pulmonary inflammatory response in CS-exposed mice was associated with a higher bacterial load that peaked at 3 dpi whilst no bacteria were detected in air mice (Fig. 1e). No bacteria were found in the lungs at 7 dpi. Finally, systemic pneumococcal dissemination peaked at 3 dpi to decline at 7 dpi. This enhanced susceptibility of CS-exposed to Sp was associated to a restricted defect in anti-microbial peptides, namely for cathelicidin, whereas levels of DefB-2 and -3 and s100a9 transcripts were similarly increased in air and CS-exposed (Supplemental Fig. 1).

These data demonstrated that chronic exposure to CS leads to delayed clearance of Sp, an effect associated with enhanced pulmonary inflammation.

Fig. 1. CS-exposed mice are more susceptible to S. pneumoniae. (2 columns). Mice were chronically exposed to CS (5 cigarettes/day, 5 days/week) over a period of 12 weeks to developmental and pulmonary responses associated to COPD. Mice were then intranasally challenged with S. pneumoniae (Sp) to induce COPD exacerbation or with PBS (Mock) as a control (a). Survival of air and CS-exposed mice was monitored for 7 days. Bacterial burden in the broncho-alveolar lavage (BAL) was determined in BAL fluid and lung tissues (b). Absolute numbers of total cells, macrophages, lymphocytes and neutrophils were determined in BAL fluids (c). Neutrophils identified as CD11b+ Ly6G+ were analyzed in lung tissues 24 h after infection (d). Histological changes were evaluated on lung sections either at 1 or 3 dpi (5 × 10^4 CFU) (e). CFU counts were evaluated in the BAL, lung tissues and blood at 1, 3 and 7 dpi (f). Data represent as mean ± SEM (n = 8–10 mice per group). *: p < 0.05 or **: p < 0.01 (one-way ANOVA test).

3.1. CS-exposed mice display delayed bacterial clearance and exacerbated inflammation upon S. pneumoniae challenge

An experimental model of COPD exacerbation was established in mice chronically exposed to Sp as the trigger (see Fig. 1a). Whereas all air mice survived when infected with 5 × 10^5 CFU, all CS-exposed mice died within a week. Thus, CS-exposed mice are more susceptible to pneumococcal infection. In contrast, after administration of 5 × 10^4 CFU per mouse, both air and CS-exposed mice survived (Fig. 1b) and allowed the analysis of airway inflammation, remodeling and immune response.

Relative to air mice, infection was associated with enhanced cellular recruitment (particularly neutrophils) in the BAL and the lungs of CS-exposed mice (Fig. 1c–d). Histological examination of lung tissues showed that inflammatory infiltrates mainly located in peribronchial areas and alveolar spaces (Fig. 1e). Moreover, a large thickening of the alveolar walls was observed in CS-exposed animal mice. In air mice challenged with bacteria, lung inflammation was nearly resolved 3 days post-infection (dpi). Enhanced pulmonary inflammatory response in CS-exposed mice was associated with a higher bacterial load that peaked at 3 dpi whilst no bacteria were detected in air mice (Fig. 1e). No bacteria were found in the lungs at 7 dpi. Finally, systemic pneumococcal dissemination peaked at 3 dpi to decline at 7 dpi. This enhanced susceptibility of CS-exposed to Sp was associated to a restricted defect in anti-microbial peptides, namely for cathelicidin, whereas levels of DefB-2 and -3 and s100a9 transcripts were similarly increased in air and CS-exposed (Supplemental Fig. 1).

These data demonstrated that chronic exposure to CS leads to delayed clearance of Sp, an effect associated with enhanced pulmonary inflammation.
3.2. CS-exposed mice display a reduced production of Th17 cytokines in response to S. pneumoniae

To investigate mechanisms involved in enhanced susceptibility to pneumococcal infection in CS-exposed mice, IL-17 and IL-22 production was quantified. Challenge with Sp significantly enhanced IL-17 and IL-22 levels in BAL (Fig. 2a) and lung lysates (data not shown) of air mice. In marked contrast, Sp infection failed to do so in mice previously exposed to CS (Fig. 2a). Whilst IL-17 remained undetectable in the serum after Sp challenge, IL-22 increase was detected in air, but not CS-exposed, animals (Fig. 2b). IFN-γ levels failed also to increase in the BAL of CS-exposed mice after Sp challenge (Supplemental Fig. 2a). Anti-CD3 restimulation of pulmonary cells induced large amounts of IL-17 whatever the animal group and a tendency to higher concentration was observed in CS-exposed mice (Fig. 2c), as well as IFN-γ (Supplemental Fig. 2b). In contrast, upon CD3 restimulation, pulmonary cells from CS-exposed animals had a much lower ability to release IL-22. Collectively, CS-exposed mice have a lower capacity to produce Th17-type cytokines upon pneumococcal challenge.

We next focused on Th17 cytokine producing cells. Infection with Sp enhanced the number, as well as the activation status (CD69 expression), of conventional T lymphocytes and NKT cells within lung tissues of air, but not CS-exposed mice (Supplementary Fig. 2c). A tendency towards an enhanced number of NK cells was noticed in both animals groups upon pneumococcal challenge whilst the number of γδ T cells and Lin-negative cells remained constant (Supplemental Fig. 2c and data not shown). Pneumococcal challenge of air mice resulted in higher frequencies of IL-17- and IL-22-producing conventional T cells, NK cells, NKT-like cells, γδ T cells and Lin-negative cells (Fig. 2d–e and data not shown). In contrast, chronic exposure to CS dramatically reduced the percentages of pulmonary IL-17-produced NK and NKT-like cells, but not conventional T cells, γδ T cells and Lin-negative cells observed after Sp challenge (Fig. 2d–e and data not shown). Percentages of IL-22-producing conventional T cells, NK cells, NKT-like cells and Lin-negative cells were also significantly diminished in infected CS-exposed mice, relative to air mice.

Hence, upon pneumococcal challenge, chronic exposure to CS leads to defective production of Th17-type cytokines by conventional T cells and innate immune cells.

3.3. CS exposure alters the function of pulmonary APC

We next hypothesized that pulmonary APC could be impacted by CS exposure to lower the activation of innate and conventional T cells to bacteria. Indeed, we and others previously reported that chronic exposure to CS alters pulmonary APC phenotype and functions (Pichavant et al., 2014; Tsoumakidou et al., 2008). Exposure to a sub-lethal dose of Sp triggered phenotypic maturation of pulmonary APC, including alveolar macrophages (AM) and dendritic cells (DC) (CD86 and II12p40 MHC; data not shown). To analyze their ability to promote Th17 cytokine production, levels of polarizing cytokines including IL-1β and IL-23 were evaluated first in lung lysates (Fig. 3a) and secondary in isolated pulmonary APC (Fig. 3b and Supplemental Fig. 3). Pneumococcal challenge strongly induced mRNA levels of IL-1β and IL-23p19 in air but not in CS-exposed mice (Fig. 3a). Sp infection also induced mRNA levels of IL-1β, IL-6, IL-23p19, but not IL-12p40, in sorted lung DC and slightly increased the expression of IL-1β and IL-12p40 transcripts in sorted AM from air mice (Supplemental Fig. 3). In CS-exposed mice, a defect in IL-1β and IL-12p40 expression was observed in AM, whereas the expression of IL-23p19 mRNA was undetectable in lung DC. At the protein level, IL-1β and IL-23 secretion was increased in supernatants of AM and DC from infected air mice, but not in cells from CS-exposed mice (Fig. 3b).

To evaluate the capacity of these sorted APC to activate T cells, lung DC and AM were cultured with isolated splenic CD4+ T cells from air mice. In these conditions, IL-22 was always undetectable (data not shown). AM (Fig. 3c) and DC (Fig. 3d) sorted from infected air mice induced significant increase in IL-17 production by CD4+ T cells, whereas antigen-presenting cells from CS-exposed mice were unable to do so. These data suggested that the defect in the Th17 response to Sp is associated with an altered function of pulmonary APC.

3.4. Exogenous IL-22 protects CS-exposed mice from S. pneumoniae infection

Since IL-17 and IL-22 production is ablated in CS-exposed mice, we questioned whether IL-17 and IL-22 supplementation by means of intranasal treatment could improve the outcome of pneumococcal infection in CS-exposed mice. We have previously demonstrated that IL-17 was critical in the development of COPD in a mouse model and higher in COPD patients than in controls (Pichavant et al., 2014). Therefore, exogenous IL-17 could have some deleterious effects during COPD exacerbations. We therefore tested the effect of exogenous IL-22 in the early control of Sp outgrowth and lung inflammation. Administration of recombinant IL-22 prior to bacterial challenge strongly reduced bacterial outgrowth in the lungs and dissemination outside the lungs (Fig. 4a). While treatment with IL-22 had no effect on neutrophil recruitment within the lungs, it enhanced the number of activated AM and DC in CS-exposed mice (Fig. 4b and Supplemental Fig. 4a), other well-known effector cells against pneumococcus. This process was also associated with an increased mobilization of NK and NKT cells in the lungs of infected COPD mice (Supplemental Fig. 4b). Of interest, administration of IL-22 resulted in enhanced levels of transcripts encoding defensin β2 (Defb2) and defensin β3 (Defb3) (Fig. 4c), both anti-microbial peptides playing a role in Sp clearance. Finally, IL-22 treatment also strongly reduced the lung lesions associated with Sp infection, namely the thickening of the alveolar walls and the inflammatory infiltrate in CS-exposed animals (Fig. 4d). This improved clearance of Sp in CS-exposed mice was also associated with higher IL-17 and IFN-γ production by lung cells (Supplemental Fig. 4c).

Together, recombinant IL-22 administration can compensate for the lack of Th17-associated cytokines in CS-exposed mice to restore anti-pneumococcal defenses.

3.5. COPD patients showed impaired Th17 cytokine production in response to S. pneumoniae

To evaluate whether COPD status modulates the response to Sp, PBMCs were isolated from 3 different groups: non-smoker healthy controls, smokers and COPD patients, and were stimulated with Sp. Levels of IL-17 and IL-22 were evaluated in PBMC supernatants. Resting PBMC exhibited similar levels of cytokines in the three groups (Fig. 5a). Exposure to Sp expectedly increased IL-22 and, to a lesser extent, IL-17 production in the non-smoker and smoker groups, but had no effect on cytokine production in COPD patients. The response to PHA was also partially altered in COPD patients, in contrast to the other two groups (data not shown).

We next looked at the cellular sources of IL-17 and IL-22, focusing on conventional T cells, NK cells, NKT cells, γδ T cells, mucosal-associated invariant T (MAIT) cells and Lineage-negative cells (Fig. 5b and Supplementary Fig. 5). In the non-smoker group, bacteria increased the proportion of IL-17-producing cells (in particular Lin−, NK and NKT cells), IL-22-producing cells (mainly NK and NKT cells) and MAIT cells (not shown). In contrast, the stimulation with Sp did not significantly amplify the proportion of cells producing these cytokines in NK, NKT and Lin− cells (Fig. 5b) as well as in MAIT cells (data not shown) from COPD patients. In smokers, IL-17 production induced by Sp was also impaired in these three cell types, whereas IL-22 expression was only reduced in NK cells. No modification of the percentage of cytokine+ cells was detected among the three groups of patients for γδT and CD4/CDB+ T cells (data not shown). This defective production of IL-17...
and IL-22 was probably linked to the lower production of IL-1β and IL-23 by PBMC from COPD patients (Fig. 5C). These data showed that the blood innate immune cells from COPD patients displayed an altered Th17 cytokine response to Sp.

4. Discussion

Infection with Sp is one of the main factors responsible for COPD exacerbation (Gaschler et al., 2007; van der Poll and Opal, 2009).
In our mouse model mimicking COPD, Sp challenge resulted in greater lung inflammation and tissue remodeling, and therefore an exacerbation of the disease. Combined exposure to CS and SEB resulted in a raised number of lymphocytes and neutrophils, epithelial remodeling and over-production of IL-17 (Huvenne et al., 2011). Gaschler et al. used *H. influenza* to exacerbate COPD and demonstrated that the bacterial burden observed in COPD mice was mainly due to a skewed inflammatory mediator expression, probably in AM (Gaschler et al., 2009). Innate immunity associated with the recruitment of competent AM and neutrophils is crucial in the early phase of natural anti-pneumococcal host defense and particularly in bacterial clearance (Clement et al., 2008). Such a pattern was observed in our model despite a defective clearance of the pathogen in CS-exposed mice.

Indeed, we observed some important modifications in the activation of APC from CS-exposed mice, but also in non conventional lymphocytes. Major cellular sources of IL-17 and IL-22, described as NK, NKT, ILC in mice and humans (Colonna, 2009; Liang et al., 2006; Sonnenberg et al., 2012; Van Maele et al., 2010), failed to produce higher levels of Th17 cytokines in response to Sp in CS-exposed mice.

**Fig. 3.** CS-exposed mice exhibited a defective response of pulmonary APC to *S. pneumoniae*. (1.5 columns). Mice were chronically exposed to air or CS over a period of 12 weeks and then intranasally challenged with 5 x 10⁴ CFU of *S. pneumoniae* (Sp) or with PBS (Mock). IL-1β and IL-23 mRNA levels were measured in lung tissues 24 h post-infection (a). CD45⁺ Siglec F⁺ AM and CD11c⁺ Ia⁺ CD64⁺ DC were sorted by flow cytometry 24 h post-infection. IL-1β and IL-23 levels were evaluated by ELISA in supernatants 24 h later (b). Cocultures were performed between sorted AM (c) or DC (d) and splenic CD4⁺ T cells purified from air mice. Supernatants were collected 48 h later and levels of IL-17 were evaluated by ELISA. Data represent mean ± SEM (n = 6–10 mice per group per experiment). One representative experiment out of three ones is shown concerning cell sorting and cocultures with T cells.
mice whereas only the production of IL-22 was altered in conventional T cells. According to the implication of such cells in the protection against Sp (Marques et al., 2012; Clement et al., 2008; Van Maele et al., 2010), this suggest that this defect might be an important determinant of bacterial susceptibility during COPD. In contrast, the activation of conventional T cells, MAIT and γδT cells was not clearly modified during COPD.

The defective activation of conventional T cells and some innate populations could be explained by the alteration of pulmonary APC, as previously reported in CS-exposed mice (Pichavant et al., 2014; Kroening et al., 2008). Indeed expression of pro-Th17 cytokines, such as IL-1β and IL-23 (Mucida and Salek-Ardakani, 2009), was decreased both in lung AM and DC from infected CS-exposed mice. IL-23 plays a key role in the clearance of the bacteria and the production of Th17 cytokines.
by ILC (Van Maele et al., 2014). IL-23 is also needed for IL-17 expression by other immune cells like NKT and γδ T-cells (Clement et al., 2008). Therefore, APC from CS-exposed mice cannot correctly educate the T cells and other innate cells to respond to Sp. Such a defective production of IL-17 and IL-23 was also observed in COPD patients in response to Sp. (Kroening et al., 2008). Altogether, during COPD, the reduced production of IL-17 and IL-22 by conventional T cells and other innate cells might result from a deficient IL-17 and IL-23 synthesis by DC in response to Sp.

Functionally, IL-17 and IL-22 have been reported as essential factors in anti-bacterial defenses. During infection, the early production of IL-17 by innate immune cells is crucial for host protective immunity (Aujla et al., 2008; Graham et al., 2011; Zheng et al., 2008) including in a role in chemo-taxis and tissue repair (Wolk et al., 2004; Zheng et al., 2008; Eyerich et al., 2010; Kolls et al., 2008; Sonnenberg et al., 2010; Witte et al., 2010). It has been recently shown that IL-17A is required for NTHi-exacerbated pulmonary neutrophilia induced by cigarette smoke although the role of IL-22 was not evaluated (Roos et al., 2015). Moreover, IL-17 and IL-22 induced the production of anti-microbial peptides (including β-defensins, S100A7/9, Reg3α and Reg3γ) important in the containment of pathogens (Zheng et al., 2008; Kolls et al., 2008; Sonnenberg et al., 2010; Cash et al., 2006). In our report, the defective production of IL-22 in CS-exposed mice to Sp was not associated to an impaired production of these antimicrobial peptides as previously reported in COPD patients (Pace et al., 2012). Nevertheless, opposite results have been reported suggesting that the levels of antimicrobial peptide expression were insufficient to control the higher bacterial load both in COPD patients and mice. We can also suspect that bacterial susceptibility in infected CS-exposed mice was not solely related with the defective production of cathelicidin, an IL-22 independent peptide involved in defense against Sp (Felgentreff et al., 2006). Interestingly, local administration of mRl-22 amplified β-defensin levels in the lungs and a competent immune response, allowing Sp clearance in CS-exposed mice. No impact on neutrophil influx was observed in infected CS-exposed mice, suggesting that the effect of this cytokine is mostly related with cell priming to efficiently kill the bacteria and/or the release of anti-microbial peptides. In these settings, the preventive role of IL-22 on lung injury is potentially linked to its complementary action on the induction of antimicrobial peptides, the activation of immune cells (including neutrophils) and in the maintenance of the epithelial barrier (Kumar et al., 2013). In infected CS-exposed animals, treatment with mRl-22 results in a efficient resolution and to the preservation of lung tissue after infection, as previously reported in inflammatory models (Liu et al., 2009). The balance between IL-17 and/or IL-22 expression has been found to contribute to either the pro-inflammatory or tissue-protective phases of lung defense, depending on the context (Liang et al., 2006; Eyerich et al., 2010; Sonnenberg et al., 2010). In our model, a protective role for IL-17 cannot be excluded (Lu et al., 2008), since the production of IL-17 was also defective in CS-exposed mice and patients in response to Sp. However, IL-17 is implicated in COPD pathogenesis. During COPD exacerbation, this cytokine has no effect on lung bacterial load and promotes the neutrophil recruitment which is potentially deleterious (Roos et al., 2015).

Alteration of the innate immune response to bacterial infection is a key determinant in the COPD course. It is now well recognized that respiratory infections are important in the induction, progression and exacerbation of the disease. Here we identified the IL-22 defect as a key factor in COPD exacerbations, both in patients and in the murine model. This alteration related to deficient activation of lymphocytes by APC offers hints for the development of novel therapeutic strategies in COPD exacerbations. Thereby, we propose IL-22 as a promising target in the treatment and/or the prevention of COPD exacerbations. Restoring this defective cytokine response could represent an ideal therapy to build a competent immune response against pathogens in COPD patients, and to limit the consequences of exacerbation of the disease.

**Conflict of interest statement**

The authors have declared that no conflict of interest exists.

**Author contributions**

Conception and design: MP and PG; analysis and interpretation: RS, OLR, CO, FH, GR, MP, BK, and PG; drafting the manuscript for important intellectual content: MP and PG. All authors gave their agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Supplementary data to this article can be found online at [http://dx. doi.org/10.1016/j.ebiom.2015.09.040](http://dx.doi.org/10.1016/j.ebiom.2015.09.040).

**Acknowledgements**

We thank the NIAID Tetramer Facility (Emory University, Atlanta, GA) for supplying CD1d tetramer and Dr. T. Camou (National Reference Laboratory, Ministry of Health, Montevideo, Uruguay) for the gift of the S. pneumoniae serotype 1 clinical isolate E1586. We also thank Hélène Bauderlique for her help for cell sorting (BICel Cytométrie Plateform, Institut Pasteur de Lille, France). A special thank to Gwénaëla Kervoaze and Eva Vilain for their technical support, and Jean-Claude Sirard, François Trottein, Isabelle Wolowczuk and Sandra Wellar for their critical reviewing of the paper.

This work was supported by the Institut National de la Santé et de la Recherche Médicale (Inserm), the Centre National de la Recherche Scientifique (CNRS) and the Conseil Régional du Nord-Pas de Calais (StreptocoP project; grant number # 13005300). Funders had no role in study design, data collection, data analysis, interpretation, writing of the report.

**References**

Agasti, A.G., Noguera, A., Sauleda, J., Sala, E., Pons, J., Buixquets, X., 2003. Systemic effects of chronic obstructive pulmonary disease. Eur. Respir. J. 21, 347–360.

Aujla, S.J., Chan, Y.K., Zheng, M., Fei, M., Askew, D.J., Pociask, D.A., Reinhart, T.A., McCullister, F., Isakov, J., Gaus, K., Husain, S., Kreindler, J.L., Dubin, P.J., Pilewski, J.M., Myerburg, M.M., Mason, C.A., Iwakura, Y., Kolls, J.K., 2008. IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. Nat. Med. 14, 275–281.

Barnes, P.J., Stockley, R.A., 2005. COPD: current therapeutic interventions and future approaches. Eur. Respir. J. 25, 1084–1106.

Cash, H.L., Whitham, C.V., Behrendt, C.L., Hooper, L.V., 2006. Symbiotic bacteria direct expression of an intestinal bactericidal lectin. Science 313, 1126–1130.

Clement, C.G., Evans, S.E., Evans, C.M., Hakewde, D., Kobayashi, R., Reynolds, P.R., Meghadam, S.J., Scott, B.L., Melicoff, E., Adachi, R., Dickey, R.F., Tuvin, M.J., 2008. Stimulation of lung innate immunity protects against lethal pneumococcal pneumonia in mice. Am. J. Respir. Crit. Care Med. 177, 1322–1330.

Colonna, M., 2009. Interleukin-22-producing natural killer cells and lymphoid tissue inducer-like cells in mucosal immunity. Immunity 31, 15–23.

Doisne, J.M., Soulard, V., Becourt, C., Amania, L., Henrot, P., Havenar-Daughton, C., Blanchet, C., Zitvogel, L., Rayfield, B., Cavaillon, J.M., Marie, J.C., Couillin, I., Benlagha, K., 2011. Cutting edge: crucial role of IL-17 and IL-22 in the innate IL-17 response of peripheral lymph node NK1.1+ invariant NKT cells to bacteria. J. Immunol. 186, 662–666.

Drannik, A.G., Pouladi, M.A., Robbins, C.S., Goncharova, S.I., Khanpour, S., Stampfl, M.R., 2004. Impact of cigarette smoke on clearance and inflammation after Pseudomonas aeruginosa infection. Am. J. Respir. Crit. Care Med. 170, 1164–1171.

Eidenschenk, C., Rutz, S., Liesenfeld, O., Ouyang, W., 2014. Role of IL-22 in microbial host defense. Curr. Top. Microbiol. Immunol. 380, 213–236.

Eyerich, S., Eyerich, K., Cavani, A., Schmidt-Weber, C., 2010. IL-17 and IL-22: siblings, not twins. Trends Immunol. 31, 354–361.

Felgentreff, K., Beisswenger, C., Griese, M., Guder, T., Bringmann, G., Bals, R., 2006. The role of NKT cells to bacteria. J. Immunol. 176, 1171–1176.

Fig. 5. COPD patients have a defective cytokine response to S. pneumoniae. (1.5 columns). Levels of IL-17 and IL-22 was quantified by ELISA in supernatants from PBMC from healthy non-smoker subjects (n = 14), healthy smokers (n = 14) and COPD patients (n = 12) (a). In parallel, percentages of IL-17 and IL-22 producing cells were measured by intracellular staining in Lin CD11c CD14 CD19 CD20 cells, NK cells and NKT cells (b). Levels of IL-17 and IL-22 were quantified by ELISA in supernatants from PBMC from healthy non-smoker subjects, healthy smokers and COPD patients (c). Data represent mean ± SEM. *: p < 0.05 versus medium in the different groups (one-way ANOVA test).
